Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 2/20 | 0.58 |
| ▸ | ARG2 | P78540 | 2/20 | 0.58 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 11/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11650757 | 1.00 | ARG1 (0.58) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15664945 | 0.89 | ARG2 (0.64) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1359695 | 0.84 | ARG1 (0.53) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1359692 | 0.84 | ARG1 (0.53) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL30085352 | 0.84 | ARG1 (0.53) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL7094527 | 0.82 | ARG2 (0.60) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL11652154 | 0.80 | CYP2D6 (0.48) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15854605 | 0.80 | ARG2 (0.54) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17393299 | 0.79 | SLC6A4 (0.47) | ARG1ARG2SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31106404 | 0.78 | ARG1 (0.47) | ARG1ARG2SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| CN-122055379-A | Compounds containing one or more diboronate esters and related insulin analogues | 普罗托莫科技公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4694932-A2 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | Protomer Technologies Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES INC. | 2025-08-07 | — | — | US | disclosed |
| CN-119677541-A | Aromatic boron-containing compounds and related insulin analogues | 原聚体科技公司 | 2025-03-21 | — | — | CN | disclosed |
| US-12214018-B2 | Glucose responsive insulins | PROTOMER TECHNOLOGIES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | PROTOMER TECH INC (US) | 2024-12-26 | — | — | US | disclosed |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-12-05 | — | — | US | disclosed |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | PROTOMER TECHNOLOGIES INC. | 2024-11-14 | — | — | US | disclosed |
| US-10640546-B2 | Non-canonical insulins and their uses | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190247468-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES, INC. | 2019-08-15 | — | — | US | disclosed |
| EP-3291828-A1 | GLUCOSE RESPONSIVE INSULINS | Mahdavi, Alborz (US) | 2018-03-14 | — | — | EP | disclosed |
| WO-2016179568-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | disclosed |
| US-7589066-B2 | Such as N-carbobenzyloxy-phenylalanyl-phenylalanylal; for treating cancer, inflammation, and/or autoimmune diseases; suppresses endogenous antigenic peptide generation | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1863513-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | The University of North Carolina at Chapel Hill (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2006-10-26 | — | — | US | disclosed |
| WO-2006099261-A2 | POTENT AND SPECIFIC IMMUNOPROTEASOME INHIBITORS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241056-A1 | Potent and specific immunoproteasome inhibitors | SERPINB1, DNPEP, PSMB2 | ARG1 1597/4885ARG2 1948/4885SLC6A2 4813/4885 |
| US-20190247468-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | ARG1 2266/4885ARG2 2786/4885SLC6A2 2935/4885 |
| US-20250249074-A1 | GLUCOSE RESPONSIVE INSULINS | GLP1R, GPR119, IAPP | ARG1 2202/4885ARG2 2799/4885SLC6A2 2940/4885 |
| US-20240425528-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND RELATED INSULIN ANALOGS | IAPP, GPR119, INSR | ARG1 2742/4885ARG2 2052/4885SLC6A2 554/4885 |
| US-12214018-B2 | Glucose responsive insulins | GLP1R, GPR119, IAPP | ARG1 2266/4885ARG2 2786/4885SLC6A2 2935/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | ARG1 415/4885ARG2 478/4885SLC6A2 2907/4885 |
| US-20240400637-A1 | COMPOUNDS CONTAINING ONE OR MORE DIBORONATES AND RELATED INSULIN ANALOGS | GPR119, INSR, IAPP | ARG1 402/4885ARG2 281/4885SLC6A2 680/4885 |
| US-20240374735-A1 | AROMATIC BORON-CONTAINING COMPOUNDS AND INSULIN ANALOGS | IAPP, GPR119, BRCA1 | ARG1 269/4885ARG2 190/4885SLC6A2 216/4885 |
| US-10640546-B2 | Non-canonical insulins and their uses | IAPP, IDE, INSR | ARG1 415/4885ARG2 478/4885SLC6A2 2907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.